Companies › Grit Biotechnology
3 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 2; Oncology, Neurology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TIL injection Autologous tumor infiltrating lymphocyte injection | – | Phase 2 | Adult; Solid Tumors, Adult; Advanced Solid Tumors | Dec 2026 |
| IB-T101 injection | – | Phase 1 | Advanced Clear Renal Cell Carcinoma | Dec 2027 |
| GT719 Injection anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Neurological Autoimmune Diseases; Hematological Malignancy (Leukemia- Lymphoma) | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05430373 | TIL injection | Phase 1 | Solid Tumors, Adult | Oncology | Dec 2026 |
| NCT06241781 | TIL injection | Phase 2 | Adult | Other | Jan 2027 |
| NCT06819293 | IB-T101 injection | Phase 1 | Advanced Clear Renal Cell Carcinoma | Oncology | Dec 2027 |
| NCT06144671 | TIL injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2027 |
| NCT06088472 | TIL injection | Phase 1 | Solid Tumors, Adult | Oncology | Dec 2027 |
| NCT07021209 | GT719 Injection | Phase 1 | Neurological Autoimmune Diseases | Neurology | Jan 2028 |
| NCT06948981 | GT719 Injection | Phase 1 | Hematological Malignancy (Leukemia- Lymphoma) | Oncology | Apr 2028 |
Juventas Cell Therapy Beijing Yongtai Ruike Biotechnology Company Miltenyi Biomedicine Takara Bio Shanghai Ming Ju Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.